The in vitro activity of itraconazole, fluconazole and amphotericin B was tested against 207 yeast strains and 3 Aspergillus fumigatus strains isolated from blood. The other 42 A. fumigatus strains were selected from respiratory tract infections. A microdilution method was employed to determine the inhibitory concentrations to restrain 70% of isolate growth (IC30). The inhibition concentrations of amphotericin B are all around the value 0.25 mg/l with a deviation of two concentration degrees, indicating sensitivity of all strains. The test results of itraconazole showed the majority of strains in the range of sensitivity (200 isolates) and low sensitivity (44 isolates). Five of 19 Candida glabrata strains demonstrated resistance to itraconazole. The results of fluconazole showed a good sensibility of C. albicans, but 4.5% of strains were resistant. Low sensitivity (1 strain) and resistance (24 strains) were evaluated for C. glabrata and C. krusei isolates. No strain of A. fumigatus was inhibited by fluconazole. The data show the necessity of in vitro tests.

Keywords:
In vitro susceptibility, Inhibitory concentration, Itraconazole, Fluconazole, Amphotericin B, Aspergillus fumigatus, Yeasts
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.